The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

Life-changing gene therapies for hemophilia have become available, yet many patients and providers have not yet rushed to try ...

Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...

General Douglas MacArthur High School senior Melody Hong has been named one of 300 semifinalists in the 2025 Regeneron ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, ...

Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $2,688.18 today based on a ...

SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

UBS downgraded Regeneron (REGN) to Neutral from Buy with a price target of $738, down from $1,130. The firm believes there is a disconnect ...

Regeneron Pharmaceuticals Inc. closed 41.92% below its 52-week high of $1,211.20, which the company reached on August 27th.

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to "Neutral" from "Buy" given uncertainty ...

A federal judge in Massachusetts reached the same heightened causation standard as applied in the court's 2023 decision in ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to ...